Fox Run Management L.L.C. Buys Shares of 30,096 Viking Therapeutics, Inc. $VKTX

Fox Run Management L.L.C. bought a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 30,096 shares of the biotechnology company’s stock, valued at approximately $1,059,000.

Other large investors have also recently bought and sold shares of the company. Havemeyer Place LP acquired a new position in shares of Viking Therapeutics in the fourth quarter valued at approximately $332,000. Parallel Advisors LLC boosted its holdings in shares of Viking Therapeutics by 117.8% in the fourth quarter. Parallel Advisors LLC now owns 10,573 shares of the biotechnology company’s stock valued at $372,000 after buying an additional 5,719 shares during the period. AXQ Capital LP acquired a new position in shares of Viking Therapeutics in the fourth quarter valued at approximately $384,000. BNP Paribas Financial Markets boosted its holdings in shares of Viking Therapeutics by 536.3% in the fourth quarter. BNP Paribas Financial Markets now owns 992,695 shares of the biotechnology company’s stock valued at $34,923,000 after buying an additional 836,686 shares during the period. Finally, Fideuram Asset Management Ireland dac acquired a new position in shares of Viking Therapeutics in the fourth quarter valued at approximately $4,732,000. Institutional investors own 76.03% of the company’s stock.

Analyst Upgrades and Downgrades

VKTX has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viking Therapeutics in a report on Monday, April 20th. Wolfe Research initiated coverage on shares of Viking Therapeutics in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $102.00 price target on shares of Viking Therapeutics in a report on Monday, March 23rd. Zacks Research upgraded shares of Viking Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 18th. Finally, BTIG Research reiterated a “buy” rating and issued a $125.00 price target on shares of Viking Therapeutics in a report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $93.60.

Viking Therapeutics Trading Down 0.0%

Shares of VKTX opened at $29.23 on Wednesday. Viking Therapeutics, Inc. has a 12 month low of $22.96 and a 12 month high of $43.15. The firm has a fifty day simple moving average of $32.11 and a 200 day simple moving average of $32.99. The stock has a market capitalization of $3.39 billion, a price-to-earnings ratio of -7.06 and a beta of 0.69.

Viking Therapeutics (NASDAQ:VKTX) last announced its earnings results on Thursday, April 30th. The biotechnology company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.36). During the same period last year, the business posted ($0.41) EPS. As a group, research analysts predict that Viking Therapeutics, Inc. will post -4.7 earnings per share for the current fiscal year.

Viking Therapeutics Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.